Research Article

Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial

David Staskin,1 Jeffrey Frankel,2 Susann Varano,3 Michael Kennelly,4 Diane K. Newman,5 Matt T. Rosenberg,6 Denise D. Shortino,7 Rachael A. Jankowich,7 and Paul N. Mudd Jr7

1Tufts University School of Medicine, Boston, MA, USA
2Seattle Urology Research Center, Seattle, WA, USA
3Clinical Research Consulting, Milford, CT, USA
4Carolinas Medical Center, Charlotte, NC, USA
5Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
6Mid-Michigan Health Centers, Jackson, MI, USA
7Urovant Sciences, Irvine, CA, USA

Correspondence should be addressed to David Staskin; staskinatt@gmail.com

Received 4 November 2021; Revised 23 February 2022; Accepted 9 March 2022; Published 13 April 2022

Academic Editor: Qing Wang

Copyright © 2022 David Staskin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Overactive bladder (OAB) is characterized by urgency and frequency with (OAB wet) or without (OAB dry) urge urinary incontinence (UUI). In the phase 3 EMPOWUR trial, vibegron—a selective β3-adrenergic receptor agonist for the treatment of OAB—significantly improved daily number of urgency episodes and micturitions vs. placebo ($P < 0.01$). These post hoc analyses aimed to compare the efficacy of vibegron vs. placebo in OAB dry and wet populations.

Methods. Patients were randomly assigned 5:5:4 to receive once-daily vibegron 75mg, placebo, or tolterodine 4mg extended release, respectively, for 12 weeks. Baseline criteria for OAB dry included an average of ≥8 micturitions, ≥3 urgency episodes, and <1 UUI episode per diary day and for OAB wet included an average of ≥8 micturitions and ≥1 UUI episode per diary day. Change from baseline in mean daily number of urgency episodes and micturitions was assessed in both populations.

Results. Of the 1463 patients included in the full analysis set, 336 (23%) had OAB dry (vibegron, N = 123; placebo, N = 115; and tolterodine, N = 98), and 1127 (77%) had OAB wet (vibegron, N = 403; placebo, N = 405; and tolterodine, N = 319). Vibegron was associated with significant reductions (95% CIs of the least squares mean differences [LSMD] does not include 0) from baseline at week 12 vs. placebo in mean daily urgency episodes for the dry (LSMD [95% CI], −1.0 [−2.0, −0.1]) and wet (−0.6 [−1.0, −0.1]) populations. Vibegron was associated with significant reductions from baseline at week 12 vs. placebo in mean daily micturitions for the dry (LSMD [95% CI], −0.8 [−1.5, −0.1]) and wet (−0.5 [−0.8, −0.1]) populations. There were no significant differences in either outcome between tolterodine and placebo for either the dry or wet populations in this study. Conclusions. In this subgroup analysis from the EMPOWUR trial, vibegron was associated with significant reductions compared with placebo in urgency episodes and micturitions in both the OAB dry and wet populations, suggesting that vibegron is similarly efficacious for these endpoints in patients with and without UUI. This trial is registered with NCT03492281.

1. Introduction

Overactive bladder (OAB) is a clinical syndrome characterized by urgency and frequency, with or without urge urinary incontinence (UUI), referred to as OAB wet and OAB dry, respectively [1, 2]. OAB is highly prevalent among US adults ≥40 years old [3], and approximately two-thirds of patients are affected by OAB dry [2, 4]. Among women, the overall prevalence of OAB dry and OAB wet is similar (7.6% and 9.3%, respectively); however, the prevalence of OAB dry
is higher than OAB wet among men (13.4% vs. 2.6%, respectively) [4]. Nevertheless, the strong and sudden urge to urinate, without or with UUI, is a cornerstone symptom that patients with OAB experience [1, 2]. Consequently, frequent urgency episodes (defined by the International Urogynecological Association and the International Continence Society as a complaint of a sudden, compelling desire to pass urine, which is difficult to defer) can significantly affect a patient’s daily functioning and productivity, with more than half of men and women (65% and 67%, respectively) reporting that their OAB symptoms impact their daily lives [2, 5]. Urinary frequency and urgency are reported more often than UUI (85% and 54% vs. 36%, respectively) [2], and urgency has been shown to be the greatest predictor of patient bother associated with OAB in both men and women [6]. Furthermore, significant reductions in health-related quality of life and increases in symptoms of depression were reported among patients with OAB experiencing urgency compared with those not experiencing urgency [7].

The standard of care for OAB is behavioral therapy with or without the use of pharmacologic treatment as a first-line treatment option [8, 9]. Anticholinergics and β3-adrenergic receptor agonists are recommended as a second-line treatment for OAB [8, 9]; however, use of anticholinergics is associated with adverse effects such as dry mouth and constipation [10], as well as an increased risk of falls [11], cognitive impairment [12], and dementia [13]. β3-adrenergic receptor agonists are available as pharmacologic treatments for OAB and are not associated with anticholinergic-related side effects such as dry mouth and cognitive impairment [10, 14, 15].

Although OAB dry affects a larger proportion of the OAB population, studies of pharmacologic treatment typically report results in the overall OAB population or in patients with OAB wet and commonly focus on UUI as the most bothersome symptom of OAB. As a result, treatment guidelines do not differentiate between patients with OAB dry or OAB wet and often neglect to address the need to manage the disruptive and core symptom of urgency associated with OAB [1]. However, one observational study has suggested that OAB wet was associated with improved outcomes after receiving solifenacin [16]. A separate observational study indicated that the presence of OAB wet predicts better efficacy outcomes with onabotulinumtoxinA [17], a third-line treatment option. Because most randomized controlled trials enroll patients with OAB irrespective of subtype or only enroll patients with OAB wet, there is limited evidence demonstrating that the available treatment options are efficacious in patients with OAB dry and effectively manage urinary urgency leading to meaningful improvements for patients.

Vibegron is a selective β3-adrenergic receptor agonist recently approved for the treatment of adult patients with OAB [18]. Vibegron acts by mediating relaxation of the detrusor muscle by selectively stimulating β3-adrenergic receptors, improving storage capacity without impeding voiding of the bladder [19, 20]. In the phase 3 EMPOWUR trial, once-daily vibegron 75 mg for 12 weeks showed statistically significant improvements compared with placebo in mean daily number of micturitions and UUI episodes (coprimary endpoints; P < 0.001, each) and in urgency episodes (key secondary endpoint; P < 0.01) [21]. It remains unknown if vibegron is equally efficacious in improving bothersome symptoms of OAB, such as frequency of micturitions and urinary urgency episodes, among patients with OAB dry vs. OAB wet. Here we present post hoc subgroup analyses from the EMPOWUR trial, comparing the efficacy of vibegron vs. placebo in the OAB dry and wet populations.

2. Methods

2.1. Study Design and Participants. Detailed methods of the full study design of the phase 3, randomized, double-blind, placebo- and active-controlled EMPOWUR trial (https://clinicaltrials.gov/ct2/show/NCT03492281) have been previously published [21]. In brief, adult patients (up to 15% of whom could be male) were enrolled if they had a history of OAB (defined as urgency, without or with UUI, usually associated with frequency and nocturia) ≥3 months prior to the screening visit. Up to 25% of patients in the EMPOWUR trial could have OAB dry, which was defined as an average of ≥8 micturitions, ≥3 urgency episodes, and <1 UUI episode per diary day based on a 7-day patient voiding diary at baseline. Criteria for OAB wet included an average of ≥8 micturitions and ≥1 UUI episode per diary day at baseline. Patients were randomly assigned 5:5:4 to receive once-daily vibegron 75 mg, placebo, or tolterodine 4 mg extended release (active control), respectively, for 12 weeks. Patients completed a voiding diary for 7 days before baseline and weeks 2, 4, 8, and 12.

The EMPOWUR trial was conducted in compliance with the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice. Investigators received institutional review board, research ethics board, or independent ethics committee approval prior to the initiation of the study. All patients provided written informed consent.

2.2. Assessments. The coprimary efficacy endpoints of the EMPOWUR trial were change from baseline at week 12 in mean daily number of micturitions and UUI episodes. UUI episodes were not assessed in this current analysis as patients with OAB dry by definition had <1 UUI episode per day at baseline. Key secondary efficacy measures included change from baseline in mean daily number of urgency episodes at week 12 and percentage of patients achieving ≥50% reduction from baseline in urgency episodes per day at week 12.

2.3. Statistical Analyses. Outcomes were assessed in the full analysis set (FAS), which included all randomized patients who received ≥1 dose of double-blind study drug and had ≥1 evaluable change from baseline micturition measurement. The FAS for the dry and wet populations was defined as all patients in the FAS meeting the definition for OAB dry or OAB wet, respectively, at study entry. A mixed model for repeated measures (MMRM) with restricted maximum likelihood estimation was used to analyze changes from
baseline at weeks 2, 4, 8, and 12 in efficacy outcomes. The covariates included in the MMRM were study visit, baseline number of urgency episodes/micturitions, and treatment by study visit interaction. Statistical significance was determined if the 95% CI of least squares mean difference (LSMD) did not include zero. The formal analysis of efficacy outcomes compared vibegron with placebo; all other efficacy outcomes including comparisons between tolerodine and placebo were considered supportive.

Among patients with OAB dry, the percentage considered responders for the urgency episodes endpoint (i.e., achieving ≥50% reduction from baseline in the mean number of daily urgency episodes) was analyzed by an additional post hoc analysis using Cochran–Mantel–Haenszel risk differences, stratified by sex (female vs. male), with weights proposed by Greenland and Robins [22]. Multiple imputation methods were used to estimate missing values for the responder endpoint of ≥50% reduction in urgency.

3. Results

3.1. Patients. Of the 1463 patients included in the overall FAS, 336 (23%) had OAB dry (vibegron, N = 123; placebo, N = 115; and active control, N = 98), and 1127 (77%) had OAB wet (vibegron, N = 403; placebo, N = 405; and active control, N = 319; Supplementary Figure 1). Overall, the mean age was 60.2 years, and most patients were white (78.3%) and enrolled in the US (89.6%; Table 1). The demographics of patients with OAB dry and wet were, in general, similar to those in the FAS. However, a higher percentage of patients with OAB dry vs. the overall OAB population were men (29.5% vs. 14.8%, respectively) and were from the US (99.1% vs. 89.6%, respectively). Correspondingly, a higher percentage of patients with OAB wet vs. OAB dry were women (89.5% vs. 70.5%, respectively). At baseline, the mean daily number of urgency episodes and micturitions were comparable between the FAS and OAB dry and wet populations.

3.2. Efficacy Endpoints

3.2.1. Mean Daily Urgency Episodes. Vibegron was associated with statistically significant reductions (95% CIs of LSMDs do not include 0) vs. placebo from baseline at week 12 in LS mean daily number of urgency episodes among patients with OAB dry (LSMD [95% CI], −1.0 [−2.0 to −0.1]) and OAB wet (LSMD of −0.6 [−1.0 to −0.1]). The LS mean (95% CI) change from baseline at week 12 in mean daily number of urgency episodes for the OAB dry population was −2.6 (−3.2 to −2.0) with vibegron vs. −1.6 (−2.2 to −0.9) with placebo and for the OAB wet population was −3.0 (−3.3 to −2.6) vs. −2.4 (−2.7 to −2.0), respectively (Table 2). In both populations, significant (95% CIs of LSMDs do not include 0) reductions from baseline were also seen with vibegron vs. placebo beginning at week 2 and were maintained at weeks 4 and 8 (Figure 1; Supplementary Table 1). No significant differences in reductions (95% CIs of LSMDs include 0) from baseline at week 12 in the mean daily number of urgency episodes were seen between tolerodine and placebo for the dry or wet populations in this study.

3.2.2. Mean Daily Micturitions. Vibegron was associated with statistically significant reductions (95% CIs of LSMDs do not include 0) vs. placebo from baseline at week 12 in LS mean daily number of micturitions among patients with OAB dry (LSMD [95% CI], −0.8 [−1.5 to −0.1]) and OAB wet (LSMD of −0.5 [−0.8 to −0.1]). The LS mean (95% CI) change from baseline at week 12 in mean daily number of micturitions for the OAB dry population was −1.8 (−2.3 to −1.3) with vibegron vs. −1.0 (−1.5 to −0.5) with placebo and for the OAB wet population was −2.1 (−2.4 to −1.9) vs. −1.7 (−1.9 to −1.5), respectively (Table 3). Significant (95% CIs of LSMDs do not include 0) reductions in the mean daily number of micturitions with vibegron compared with placebo were seen as early as week 4 for patients with OAB dry and at week 2 for patients with OAB wet and were maintained through week 8 (Figure 2; Supplementary Table 2). No significant differences in reductions (95% CIs of LSMD include 0) from baseline at week 12 in the mean daily number of micturitions were seen between tolerodine and placebo for the dry or wet populations in this study.

3.2.3. Responder Analysis for Urgency Episodes. A significantly greater percentage of patients with OAB dry treated with vibegron compared with placebo achieved ≥50% reduction from baseline at week 12 in urgency episodes (36.9% vs. 23.1%, respectively; nominal P < 0.05; Figure 3). No significant differences were observed from baseline at week 12 in urgency episodes between tolerodine and placebo (29.0% vs. 23.1%, respectively; nominal P > 0.05) for patients with OAB dry in this study.

4. Discussion

In this subgroup analysis of patients with OAB dry and wet from the phase 3 EMPOWER trial, treatment with vibegron was associated with significant improvements from baseline at week 12 in mean daily number of urgency episodes and micturitions compared with placebo. No significant differences were observed between tolerodine and placebo for either outcome in either the OAB dry or wet populations in this study. Statistically significant reductions in urgency episodes and micturitions were observed with vibegron vs. placebo as rapidly as weeks 2 and 4, respectively, and were sustained throughout the 12-week treatment period. In addition, a significantly greater percentage of patients with OAB dry receiving vibegron compared to placebo achieved a clinically meaningful improvement (≥50% reduction) in urgency episodes per day at week 12. Similarly, in patients with OAB wet, treatment with vibegron was associated with statistically significant improvement compared with placebo from baseline in mean daily number of urgency episodes and micturitions beginning at week 2, which was maintained through week 12.

While UUI is a commonly studied symptom of OAB, a survey of >16,000 individuals showed that, among respondents reporting symptoms of OAB, frequency and urgency are the most commonly reported, occurring in 85% and 54% of respondents, respectively [2]. The urgent and
had improvement than those without incontinence [16, 17], that patients with OAB wet may experience greater improvement than those with OAB dry (≥0.01) [6, 23]. Furthermore, the degree of patient-reported bother of OAB symptoms has been shown to be the strongest predictor of patient bother (greater than UUI, frequency, or nocturia) associated with OAB in both men and women (P < 0.01) [6, 23].

Although OAB dry affects two-thirds of patients with OAB [2, 4], most clinical trials have reported efficacy outcomes overall or in patients with OAB wet. Results from studies reporting by OAB subtype, however, often suggest that patients with OAB wet may experience greater improvement than those without incontinence [16, 17], highlighting the importance of assessing efficacy outcomes in patients with and without UUI. In our analyses, treatment with vibegron was associated with slightly greater reductions in patients with and without UUI. In our analyses, treatment with vibegron was associated with slight greater reductions in patients with and without UUI. In our analyses, treatment with vibegron was associated with slight greater reductions in patients with and without UUI. In our analyses, treatment with vibegron was associated with slight greater reductions in patients with and without UUI.

Table 1: Demographics and baseline clinical characteristics of patients with OAB dry and wet from the EMPOWUR trial.

| Characteristic                  | Placebo (N = 115) | Placebo (N = 405) | Placebo (N = 520) | Placebo (N = 417) | Vibegron (N = 123) | Vibegron (N = 403) | Vibegron (N = 526) | Tolterodine (N = 98) | Tolterodine (N = 319) | Tolterodine (N = 417) |
|--------------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| Mean (SD) age, y               | 59.5 (14.6)       | 60.0 (13.0)       | 59.9 (13.3)       | 59.8 (13.2)       | 59.4 (14.0)       | 61.2 (13.1)       | 60.8 (13.3)       | 60.8 (13.3)       |                   |                   |
| ≥65, n (%)                     | 52 (45.2)         | 168 (41.5)        | 220 (42.3)        | 166 (39.8)        | 50 (40.7)         | 192 (47.6)        | 242 (46.0)        | 242 (46.0)        |                   |                   |
| ≥75, n (%)                     | 13 (11.3)         | 44 (10.9)         | 57 (11.0)         | 47 (11.3)         | 16 (13.0)         | 59 (14.6)         | 75 (14.3)         | 75 (14.3)         |                   |                   |
| Gender, n (%)                  | Women             | 81 (70.4)         | 364 (89.9)        | 445 (85.6)        | 88 (71.5)         | 361 (86.9)        | 449 (85.4)        | 449 (85.4)        |                   |                   |
|                                | Men               | 34 (29.6)         | 41 (10.1)         | 65 (15.6)         | 35 (28.5)         | 42 (10.4)         | 35 (11.0)         | 35 (11.0)         |                   |                   |
| Race, n (%)                    | White             | 81 (70.4)         | 325 (80.2)        | 406 (78.1)        | 100 (81.3)        | 322 (79.9)        | 422 (80.2)        | 317 (76.0)        |                   |                   |
|                                | Black or African  | 20 (17.4)         | 59 (14.6)         | 79 (15.2)         | American         | 18 (14.6)         | 56 (13.9)         | 74 (14.1)         | 69 (16.5)         |                   |
|                                | Asian             | 12 (10.4)         | 17 (4.2)          | 29 (5.6)          | Others           | 3 (2.4)           | 24 (6.0)          | 27 (5.1)          | 26 (6.2)          |                   |
|                                | Others            | 2 (1.7)           | 4 (1.0)           | 6 (1.2)           |                 | 2 (1.6)           | 1 (0.2)           | 5 (1.2)           |                   |                   |
| Region, n (%)                  | US                | 114 (99.1)        | 349 (86.2)        | 463 (89.0)        | 123 (100.0)       | 349 (86.6)        | 472 (89.7)        | 376 (90.2)        |                   |                   |
|                                | Non-US            | 1 (0.9)           | 4 (1.0)           | 6 (1.2)           |                 | 2 (2.0)           | 1 (0.2)           | 5 (1.2)           |                   |                   |
| Mean (SD) urgency episodes per day | 8.6 (5.0)     | 8.6 (5.0)         | 8.6 (4.4)         | 3.3 to 2.0        | 12 (3.4)         | 8.4 (3.9)         | 1.0 to 0.1        |                   |                   |
| Mean (SD) micturitions per day | 11.9 (3.8)        | 11.7 (4.1)        | 11.4 (3.3)        |                   | 11.3 (3.5)        | 11.6 (3.0)        | 11.3 (3.4)        |                   |                   |
|                                | 60.8 (13.3)       | 59.5 (12.4)       | 60.7 (12.4)       | 59.9 (13.3)       | 60.2 (14.3)       | 59.8 (13.2)       |                   |                   |

Table 2: Change from baseline at week 12 in mean daily number of urgency episodes.

| Change from baseline at week 12 | Placebo (N = 115) | Vibegron (N = 123) | Tolterodine (N = 98) | Placebo (N = 405) | Vibegron (N = 403) | Tolterodine (N = 319) |
|--------------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| LS mean (SE)                   | -1.6 (0.34)       | -2.6 (0.33)       | -2.0 (0.36)       | -2.4 (0.17)       | -3.0 (0.17)       | -2.8 (0.19)       |
| 95% CI                         | -2.2 to -0.9      | -3.2 to -2.0      | -2.7 to -1.3      | -2.7 to -2.0      | -3.3 to -2.6      | -3.2 to -2.4      |
| Active = placebo               |                   |                   |                   |                   |                   |                   |
| LSMD (SE)                      | -1.0 (0.47)       | -0.4 (0.49)       |                   | -0.6 (0.24)       | -0.4 (0.26)       |                   |
| 95% CI                         | -2.0 to -0.1      | -1.4 to 0.5       |                   | -1.0 to -0.1      |                   |                   |

LS, least squares; LSMD, LS mean difference. Analyzed using a mixed model for repeated measures with covariates for study visit, baseline number of urgency episodes, and treatment by study visit interaction. All randomized patients with OAB dry at study entry who took ≥1 dose of double-blind study treatment and had ≥1 evaluable change from baseline micturition measurement. All randomized patients with OAB wet at study entry who took ≥1 dose of double-blind study treatment and had ≥1 evaluable change from baseline micturition measurement. All randomized patients who took ≥1 dose of double-blind study treatment and had ≥1 evaluable change from baseline micturition measurement.
OAB dry, it is important to note that treatment with vibegron was associated with significant improvement vs. placebo in OAB symptoms of urgency and micturition frequency in patients with OAB dry, extending results from the overall population. These results contrast previous reports showing significantly greater efficacy in patients with OAB wet and show that vibegron is similarly efficacious among patients without or with UUI. As treatment
Table 3: Change from baseline at week 12 in mean daily number of micturitions).

|                          | Dry population  | Wet population |
|--------------------------|-----------------|----------------|
| Placebo (N = 115)        | 103             | 372            |
| Vibegron (N = 123)       | 109             | 383            |
| Tolterodine (N = 98)     | 92              | 286            |

**Change from baseline at week 12**

|                          | LS mean (SE)    | 95% CI         | LSMD (SE)     | 95% CI         |
|--------------------------|-----------------|----------------|---------------|----------------|
| Placebo (N = 115)        | -1.0 (0.26)     | -1.5 to -0.5   | -0.8 (0.36)   | -0.5 to -0.1   |
| Vibegron (N = 123)       | -1.8 (0.25)     | -2.3 to -1.3   | -0.3 (0.38)   | -1.1 to 0.4    |
| Tolterodine (N = 98)     | -1.3 (0.28)     | -1.9 to -0.8   | - -           | -0.8 to -0.1   |
| Placebo (N = 405)        | -1.7 (0.12)     | -1.9 to -1.5   | -0.5 (0.17)   | -0.6 to 0.1    |
| Vibegron (N = 403)       | -2.1 (0.12)     | -2.4 to -1.9   | -0.3 (0.18)   | -       |
| Tolterodine (N = 319)    | -2.0 (0.13)     | -2.2 to -1.7   | -       |

LS, least squares; LSMD, LS mean difference. *Analyzed using a mixed model for repeated measures with covariates for study visit, baseline number of micturitions, and treatment by study visit interaction. ‡All randomized patients with OAB dry who took ≥1 dose of double-blind study treatment and had ≥1 evaluable change from baseline micturition measurement. §All randomized patients with OAB wet who took ≥1 dose of double-blind study treatment and had ≥1 evaluable change from baseline urge urinary incontinence measurement.

![Figure 2: Continued.](a)
guidelines do not differentiate between OAB subtypes [1], these results suggest that vibegron can be a valuable pharmacologic treatment for patients with OAB irrespective of subtype. Clinically meaningful decreases with vibegron in urinary urgency, arguably the most bothersome symptom of OAB, address a need in the treatment of OAB to effectively manage urgency episodes to improve patient outcomes.

A potential limitation of these post hoc analyses is the relatively high placebo response that varied between the OAB dry and wet populations, but this observation is consistent with past OAB studies. Furthermore, the sample size for the EMPOWUR trial was calculated based on the overall patient population, and the trial was therefore not powered to detect significant differences between treatments in either subgroup.
5. Conclusions

In this post hoc analysis of patients with OAB dry and OAB wet, treatment with once-daily vibegron 75 mg was associated with significant improvement vs. placebo in urgency episodes and micturitions in both populations. These results are consistent with the results from the EMPOWUR study showing that vibegron significantly improves symptoms of OAB. Patients with OAB dry or OAB wet receiving vibegron experienced similar symptomatic improvements of OAB, including urinary urgency and micturitions, indicating that vibegron is similarly efficacious for these endpoints in patients with or without UUI.

Data Availability

Requests for the data from Urovant Sciences (e-mail: medinfo@urovant.com) will be considered from qualified researchers on a case-by-case basis.

Disclosure

Parts of these data have been previously presented at the 2021 American Urological Association (AUA) Virtual Meeting (September 10–13, 2021), at the International Continence Society 2021 Online Meeting (October 14–17, 2021), at regional AUA meetings (South Central Section of the AUA [September 29–October 2, 2021; Scottsdale, AZ], North Central Section of the AUA [October 6–9, 2021; Chicago, IL], New England Section of the AUA [October 14–16, 2021; Burlington, VT], and Western Section of the AUA [October 31–November 4, 2021; Indian Wells, CA], and at the 2021 Society of Urologic Nurses and Associates uroLogic Conference (October 28–31, 2021; St Louis, MO).

Conflicts of Interest

DS is an advisor for Astellas, Urovant Sciences, and UroCure; a meeting participant, lecturer, and investigator for Astellas and Urovant Sciences; and holds other interests in UroCure. JF is an investigator for Urovant Sciences, an investigator and speaker for Astellas Pharma and Pfizer Inc., and a speaker for Tolmar Inc. SV is a consultant and investigator and speaker for Astellas Pharma and Pfizer Inc., and a speaker for Tolmar Inc. MR is a consultant and speaker for Urovant Sciences; a consultant and speaker for Astellas Pharma; and a consultant for Ferring. DDS, RJ, and PNM were employees of Urovant Sciences at the time the work was conducted.

Acknowledgments

Medical writing and editorial support was provided by Lauryn Samelko, PhD, and Krystina Neuman, PhD, CMPP, of The Curry Rockefeller Group, LLC (Tarrytown, NY). This study and the medical writing and editorial support for the preparation of this manuscript were funded by Urovant Sciences (Irvine, CA).

Supplementary Materials

Supplementary Table 1. Change from baseline in mean daily number of urgency episodes. Supplementary Table 2. Change from baseline in mean daily number of micturitions. Supplementary Figure 1. Patient disposition. (Supplementary Materials)

References

[1] E. A. Gormley, D. J. Lightner, K. L. Burgio et al., Diagnosis and Treatment of Overactive Bladder (Non-neurogenic) in Adults: AUA/SUFU GuidelineAmerican Urological Association, 2019.
[2] I. Milsom, P. Abrams, L. Cardozo, R. G. Roberts, J. Thüröf, and A. J. Wein, “How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study,” BJU International, vol. 87, no. 9, pp. 760–766, 2001.
[3] K. S. Coyne, C. C. Sexton, V. Vats, C. Thompson, Z. S. Kopp, and I. Milsom, “National community prevalence of overactive bladder in the United States stratified by sex and age,” Urology, vol. 77, no. 5, pp. 1081–1087, 2011.
[4] W. F. Stewart, J. Van Rooyen, G. Cundiff et al., “Prevalence and burden of overactive bladder in the United States,” World Journal of Urology, vol. 20, no. 6, pp. 327–336, 2003.
[5] B. T. Haylen, D. de Ridder, R. M. Freeman et al., “An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction,” Neuro-urology and Urodynamics, vol. 29, no. 1, pp. 4–20, 2010.
[6] I. Milsom, S. A. Kaplan, K. S. Coyne, C. C. Sexton, and Z. S. Kopp, “Effect of bothersome overactive bladder symp-toms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from Epi-LUTS,” Urology, vol. 80, no. 1, pp. 90–96, 2012.
[7] K. S. Coyne, C. Payne, S. K. Bhattacharyya et al., “The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey,” Value in Health, vol. 7, no. 4, pp. 455–463, 2004.
[8] E. A. Gormley, D. J. Lightner, M. Faraday, S. P. Vasavada, and American Urological Association, “Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment,” The Journal of Urology, vol. 193, no. 5, pp. 1572–1580, 2015.
[9] D. J. Lightner, A. Gomelsky, L. Souter, and S. P. Vasavada, “Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019,” The Journal of Urology, vol. 202, no. 3, pp. 558–563, 2019.
[10] K. Maman, S. Aballea, J. Nazir et al., “Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison,” European Urology, vol. 65, no. 4, pp. 755–765, 2014.
S. M. Szabo, K. Gooch, C. Schermer et al., “Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study,” *BMJ Open*, vol. 9, no. 5, Article ID e026391, 2019.

C. Fox, T. Smith, I. Maidment et al., “Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review,” *Age and Ageing*, vol. 43, no. 5, pp. 604–615, 2014.

C. A. C. Coupland, T. Hill, T. Dening, R. Morriss, M. Moore, and J. Hippisley-Cox, “Anticholinergic drug exposure and the risk of dementia: a nested case-control study,” *JAMA Internal Medicine*, vol. 179, no. 8, pp. 1084–1093, 2019.

T. L. Griebling, N. L. Campbell, J. Mangel et al., “Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR),” *BMC Geriatrics*, vol. 20, no. 1, Article ID 109, 2020.

S. Su, L. Liang, J. Lin, L. Liu, Z. Chen, and Y. Gao, “Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder,” *Medicine*, vol. 100, no. 5, Article ID e23171, 2021.

S.-M. Hsiao, H.-H. Lin, and H.-C. Kuo, “Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome,” *Neurology and Urodynamics*, vol. 33, no. 3, pp. 331–334, 2014.

S.-M. Hsiao, H.-H. Lin, and H.-C. Kuo, “Factors associated with therapeutic efficacy of intravesical OnabotulinumtoxinA injection for overactive bladder syndrome,” *PLoS One*, vol. 11, no. 1, Article ID e0147137, 2016.

Urovant Sciences, Inc. GEMTESA®. Vibegron, Irvine, CA 2020.

S. D. Edmondson, C. Zhu, N. F. Kar et al., “Discovery of vibegron: a potent and selective β3 adrenergic receptor agonist for the treatment of overactive bladder,” *Journal of Medicinal Chemistry*, vol. 59, no. 2, pp. 609–623, 2016.

J. Di Salvo, H. Nagabukuro, L. A. Wickham et al., “Pharmacological characterization of a novel beta 3 adrenergic agonist, vibegron: evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 360, no. 2, pp. 346–355, 2017.

D. Staskin, J. Frankel, S. Varano, D. Shortino, R. Jankowich, and P. N. Mudd Jr, “International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR,” *The Journal of Urology*, vol. 204, no. 2, pp. 316–324, 2020.

S. Greenland and J. M. Robins, “Estimation of a common effect parameter from sparse follow-up data,” *Biometrics*, vol. 41, no. 1, pp. 55–68, 1985.

C. P. Vaughan, T. M. Johnson, M. A. Ala-Lipasti et al., “The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population-based FINNO study,” *European Urology*, vol. 59, no. 4, pp. 629–636, 2011.

A. Rantell, L. Cardozo, and V. Khullar, “Personal goals and expectations of OAB patients in the UK,” *Neurology and Urodynamics*, vol. 36, no. 4, pp. 1194–1200, 2017.

K. S. Coyne, C. C. Sexton, Z. S. Kopp, C. Ebel-Bitoun, I. Milsom, and C. Chapple, “The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS,” *BJU International*, vol. 108, no. 9, pp. 1459–1471, 2011.